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ABSTRACT
Tumor-associated macrophages (TAMs) play a role in tumor development and progression. We
hypothesized that abundance of TAMs might modify efﬁcacy of 5-ﬂuorouracil chemotherapy in colorectal
cancer. We measured the density of CD68C TAMs at the invasive front of primary tumor of colorectal
carcinoma (PT-TAMs; n D 208), at available matched metastatic lymph node (LN-TAMs; n D 149), and in an
independent set of primary colorectal cancers (PT-TAMs, n D 111). The hazard ratios for disease-free
survival were computed by Cox proportional-hazards model. In exploratory analysis, the interaction
between TAMs and 5-ﬂuorouracil adjuvant therapy was signiﬁcant (PT-TAMs, p D 0.02; LN-TAMs, p D
0.005). High TAMs were independently associated with better disease-free survival only in 5-ﬂuorouracil-
treated patients (PT-TAMs, HR 0.23; 95%CI, 0.08–0.65; p D 0.005; LN-TAMs, HR 0.13; 95%CI, 0.04–0.43; p D
0.001). The independent predictive value of PT-TAMs was replicated in the external set (HR, 0.14; 95%CI
0.02–1.00; p D 0.05). In an in vitro experiment, 5-ﬂuorouracil and macrophages showed a synergistic effect
and increased colorectal cancer cell death. High densities of TAMs, particularly in metastatic lymph-nodes,
identify stage III colorectal cancer patients beneﬁtting from 5-ﬂuorouracil adjuvant therapy.
Abbreviations: TAMs, Tumor-associated macrophages; TANs, tumor-associated neutrophils; PT-TAMs, TAMs at the
invasive front of primary tumors; LN-TAMs, () TAMs in the nodal metastasis; IRA, immune-reactive area
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Introduction
Adjuvant chemotherapy is the standard post-surgical treatment
of patients with stage III colorectal cancer. In this setting, ﬂuo-
ropyrimidines improve 5-year survival rates by 10–15%, an
additional 4–6% being contributed by their combination with
oxaliplatin.1-3 Even among patients receiving adjuvant therapy,
one third still progresses to metastatic disease,4-6 a rate not
improved by biologic agents.5,7-9 These facts indicate that
mechanisms of disease eradication achieved by chemotherapy
are unlikely to cooperate with those of disease control exerted
by biologic agents,10 putting forward the lack of markers pre-
dicting the efﬁcacy of chemotherapy in stage III colorectal
cancer. Molecular features which deﬁne colorectal cancer sub-
types with heterogeneous prognosis (such as KRAS/BRAF and
microsatellite status), do not predict responsiveness to adjuvant
chemotherapy10,11 as they do in metastatic setting, or alike
PI3K-mutations toward aspirin responsiveness in adjuvant set-
ting.12 Also tumor-inﬁltrating lymphocytes (TILs), which effec-
tively forecast the outcome of patients with early colorectal
cancer, are unlikely to act as predictive factor in node-positive
patients.13-16 Under this respect, other key players of the tumor
microenvironment deserving consideration are the tumor-asso-
ciated macrophages (TAMs). Acting as promoters of cancer
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progression,17,18 their high density usually correlates with worse
prognosis, with the notable exceptions of colorectal cancer.19-24
However, in some neoplastic disease, such as follicular lympho-
mas, TAM prognostic impact heavily depends upon treat-
ment.25-27 Preclinical studies have also depicted a complex dual
role for TAMs in modulating the response to anticancer thera-
pies.28-30 In some cancers, selected chemotherapeutic agents
enhance the anti-tumor activity of TAMs by eliciting adaptive
responses able to determine immunogenic cell death,31,32 by
depleting immunosuppressive TAMs,33,34 or by reprogram-
ming macrophages to an antitumor phenotype.35,36 Although
scanty clinical data are available on interactions of TAMs with
chemotherapy efﬁcacy in solid tumors, high loads of TAMs
correlated with prolonged survival in 5-ﬂuorouracil-treated
patients with gastric cancer,37 and partially corrected the poor
prognosis of patients resected for pancreatic cancer and treated
with adjuvant gemcitabine.38 In keeping with these data, we
recently reported the favorable prognostic interaction of 5-ﬂuo-
rouracil adjuvant therapy in colorectal cancer patients with
high densities of tumor-associated neutrophils (TANs), a native
component of the tumor inﬁltrate otherwise associated with
poor clinical outcome.39-41
This study was aimed to see whether the favorable prognos-
tic association between TAMs densities and colorectal cancer
outcome reﬂects a beneﬁcial interaction of macrophages with
5-ﬂuorouracil-based adjuvant chemotherapy. To this aim, the
predictive value of TAMs at the invasive front of primary
tumors (PT-TAMs) and of nodal metastasis (LN-TAMs) was
tested in a consecutive series of stage III colorectal cancer, and
in external set of primary tumors. In vitro we conducted experi-
ments investigating the interplay of 5-ﬂuorouracil with macro-
phages in determining colorectal cancer cell death.
Results
Densities of TAMs in primary tumors and in metastatic
lymph nodes
Patient demographics, clinico-pathological, and molecular fea-
tures of 208 stage III colorectal cancers are detailed in the
Table S1. CD68-immunoreactive cells were present in most of
tumors samples, both at the invasive front of primary cancers
(186 of 208; 89.4%), and in metastatic lymph nodes (141 of
149; 94.6%). The more dense PT-TAM (median IRA%, 3.95 %;
2nd-3rd quartile, 1.65–8.38) and the less dense LN-TAM
(median IRA%, 2.25 %; 2nd-3rd quartile, 0.75–5.24; p < 0.001)
contents were signiﬁcantly related (linear correlation p <
0.001, Pearson’s r D 0.37). Overall, PT-TAM densities in the
institutional cohort (n D 208; median 3.80%; 2nd-3rd quartile,
1.47–8.19) were not different (p D 0.50) from those of the
external set of primary cancers (n D 111; median 4.36 %; 2nd-
3rd quartile, 2.12–6.99).
As to pathological features (Table S2), lower densities of PT-
TAMs were associated with deeper tumor local invasion
(pT4 vs. pT3, p D 0.01), atypical tumor histology (mucinous or
medullary vs. adenocarcinoma, p D 0.03), and low amounts of
CD3-TILs (p<0.001).
However, TAM densities were similar for the 3rd (PT-TAM
median, 4.74%) and 4th (5.57%; p D 0.88) TIL quartiles.
The density of TAMs was not signiﬁcantly associated with
patient demographics, with the administration adjuvant ther-
apy, nor with tumor molecular features.
No signiﬁcant association between PT-TAMs densities and
clinical-pathological variables was detected in the external vali-
dation set (CD3C TILs not determined).
Prognostic interaction of tumor-associated macrophages
and neutrophils with 5-ﬂuorouracil adjuvant therapy
The impact of TAM density on the risk of postoperative recur-
rences is shown in Table 1. At univariate Cox analysis, high densi-
ties of both PT- and LN-TAMs were signiﬁcantly associated with
a lower risk of postsurgical recurrence (p D 0.006 and p D 0.001,
respectively). Other variables signiﬁcantly associated with a more
favorable outcome included age<70 y (pD 0.01), N1 nodal status
(p D <0.001), absence of vascular invasion (p<0.001), and post-
operative treatment with 5-ﬂuorouracil (pD 0.04).
Interaction analysis revealed signiﬁcant prognostic inter-
actions of 5-ﬂuorouracil adjuvant therapy with PT-TAMs
(p D 0.02), with LN-TAMs (p D 0.005), and with density
of intra-tumoral neutrophils (TANs, p D 0.01). In accor-
dance with the Cox model, Kaplan-Meier curves of disease-
free survival (Fig. 1) showed that increasing densities of
PT-TAMs (p D 0.005) and of LN-TAMs (p< 0.001) were
signiﬁcantly associated with a better prognosis only in
patients treated with 5-ﬂuorouracil adjuvant therapy. In
particular, 5-ﬂuorouracil-treated patients with highest (4th
quartile) densities of TAMs had a 5-year disease-free sur-
vival much better than that of corresponding patients oper-
ated for cancers with lower densities of macrophages (PT-
TAMs, 89.7% vs. 60.8%, p D 0.001; LN-TAMs, 88.6% vs.
58.0%, p D 0.008). Also the 4th quartile of intra-tumoral
neutrophils (TANs) was weakly (p D 0.04) associated with
better disease-free survival in 5-ﬂuorouracil-treated patients
(Fig. S1). In contrast, no association of TAMs and TANs
densities with disease-free survival was observed in the sub-
set of patients not treated with adjuvant therapy.
Predictive value of tumor-associated macrophages
and neutrophils
Receiving Operator Characteristic (ROC) curves (Fig. S2) were
used to determine optimal cutoffs of TAMs and TANs densities
predicting colorectal cancer recurrences in 5-ﬂuorouracil-
treated patients. Optimal cut-offs were 8.0% immune-reactive
area for PT-TAMS, 3.7% for LN-TAMs, and 1.16 % for TANs,
values slightly lower than the inferior limits of 4th-quartile sub-
classes (9.2%, 5.5%, and 1.35%, respectively). According to the
cut-off values, patients were grouped in high or low densities of
TAMs and TANs. At Kaplan-Meier curves (Fig. 2), 5-ﬂuoroura-
cil-treated patients with high PT-TAMs, or high LN-TAMs,
showed a signiﬁcantly better disease-free survival than patients
with low densities of macrophages (5-year disease-free survival:
by PT-TAMs, 90.2% vs. 60.0%, p D 0.0008; by LN-TAMs,
92.2% vs. 50.2%, p<0.0001). Also high TAN densities were
associated with better outcome (p D 0.04; Fig. S3).
Survival curves of patients from the external validation set (for
which disease-speciﬁc survival data were available) conﬁrmed the
e1342918-2 A. MALESCI ET AL.
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better outcome of 5-ﬂuorouracil-treated patients with high densi-
ties of PT-TAMs (p D 0.03), together with the lack of any impact
on the outcome of untreated subjects (pD 0.62) (Fig. S4).
At Cox univariate analysis (Table 2), high PT-TAMs (p D
0.002), high LN-TAMs (p D 0.001), high TANs (p D 0.04), N1
nodal status (p<0.001), and absence of vascular invasion (p D
0.008), were associated with better disease-free survival of 5-
ﬂuorouracil-treated patients from the institutional cohort. A
favorable predictive value of high PT-TAMs (p D 0.05), N1
nodal status (p D 0.03), and absence of vascular invasion (p D
0.05) was also observed in the external set. In multivariate mod-
els adjusted by nodal status and vascular invasion (Table 3),
only PT-TAMs (p D 0.005) and LN-TAMs (p D 0.001) main-
tained an independent predictive value. PT-TAMs resulted to
be an independent outcome predictor also in the external vali-
dation set (p D 0.05).
Synergic colorectal cancer cell killing by macrophages
and 5-ﬂuorouracil
At ﬂuorescence-activated cell sorting (FACS), the death rate of
SW480 cells was not increased by short-term (24-hour) expo-
sure to 10 mM 5-ﬂuorouracil (Fig. 3A, top panels), even if can-
cer cells were co-cultured with un-polarized macrophages
(Fig. 3A, middle panels). In contrast, co-culture of tumor cells
with M1-polarized macrophages (Fig. 3A, bottom panels)
almost doubled the cell death rate, which was further increased
by exposure to 5-ﬂuorouracil.
Table 1. Risk of postoperative recurrence in stage III colorectal cancer by TAM densities, clinical-pathological features, and 5-ﬂuorouracil (5FU) adjuvant therapy.
Cox Proportional Hazard Models
Recurrences
Univariate Analysis
Interaction with 5FU Therapy
No. (%) HR (95% CI) p p
Densities of Tumor-Associated Macrophagesa
PT-TAMs, (quartiles) 1st 24/52 (46.1) 1 (reference)
2nd ¡3rd 35/104 (33.6) 0.70 (0.42–1.18) 0.006 0.02
4th 11/52 ( 21.1) 0.37 (0.18–0.76)
LN-TAMs (quartiles) 1st 21/37 (56.7) 1 (reference)
2nd-3rd 23/75 (30.7) 0.47 (0.26–0.85) 0.001 0.005
4th 8/37 (21.6) 0.29 (0.13–0.65)
Patient Demographics
Age 70 yrs. 38/90 (42.2) 1 (reference) 0.01 0.21
<70 yrs. 32/118 (27.1) 0.55 (0.35–0.89)
Gender male 41/127 (32.3) 1 (reference) 0.60 0.78
female 29/81 (35.8) 1.13 (0.70–1.83)
Tumor Pathology
Siteb distal 46/134 (34.3) 1 (reference) 0.96 0.26
proximal 24/74 (32.4) 0.99 (0.60–1.62)
Local Invasion pT3 57/196 (29.1) 1 (reference) 0.32 0.29
pT4 13/32 (40.6) 1.35 (0.74–2.47)
Nodal Invasionc N1 32/136 (23.5) 1 (reference) <0.001 0.97
N2 38/72 (52.8) 2.82 (1.76–4.53)
Graded G1/G2 48/157 (30.6) 1 (reference) 0.05 0.92
G3 22/51 (43.1) 1.65 (0.99–2.73)
Cell-Typee ADC 60/182 (33.0) 1 (reference) 0.51 0.51
Variants 10/26 (38.5) 1.25 (0.64–2.44)
Density of TILsf (quartiles) 1st 19/52 (36.5) 1 (reference) 0.99
2nd¡3rd 34/104 (32.7) 0.89 (0.51–1.57) 0.76
4th 17/52 (32.7) 0.90 (0.47–1.74)
Density of TANsg (quartiles) 1st-to-3rd 50/148 (33.8) 1 (reference) 0.27 0.01
4th 13/52 (25.0) 0.71 (0.38–1.30)
Vascular Invasion no 37/144 (25.7) 1 (reference) <0.001 0.65
yes 33/64 (51.6) 2.49 (1.56–4.00)
Tumor Molecular Features
MS Statush MSS 65/183 (35.5) 1 (reference) 0.22 0.91
MSI 5/25 (20.0) 0.56 (0.23–1.40)
BRAF wild-type 64/194 (33.0) 1 (reference) 0.36 0.87
mutated 6/14 (42.8) 1.47 (0.64–3.41)
K-RAS wild-type 1 (reference) 0.52 0.43
mutated 1.18 (0.71–1.97)
Post-surgical treatment
5FU Therapy yes 44/146 (30.1) 1 (reference) 0.04 —
no 26/62 (41.9) 1.67 (1.02–2.70)
apercent CD68-immunoreactive area (mean of values from 3 distinct microscopic ﬁelds) at the invasive front of primary tumors (PT-TAMs) or of metastatic lymph nodes
(LN-TAMs), in a consecutive series of 208 stage III colorectal cancers; nodal tissues available in 149 cases
bto splenic ﬂexure
cN1, 1–3 regional lymph nodes involved; N2,  4 nodes
dG1/G2, well-to moderately differentiated; G3, poorly differentiated.
evariants include mucinous, signet-ring, or medullary histo-type
fTILs, tumor-inﬁltrating CD3C lymphocytes at the invasive front of the primary tumor
gTANs, CD66bC tumor-associated neutrophils in the intra-tumoral compartment (PT-TANs); no detectable immune-reactivity in 80 of 200 (40%) tested tissues
hMSS, microsatellite-stable; MSI, microsatellite-unstable
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In independent experiments with SW480 and HT29 cells,
the tumoricidal activity induced by co-culture with M1-macro-
phages and 5-ﬂuorouracil exposure exceeded the sum of the
cytotoxic effects of macrophages and 5-ﬂuorouracil alone
(Fig. 3B). Cancer cells co-cultured wit M1-macrophages and
exposed to 5-ﬂuorouracil had a death rate signiﬁcantly superior
to that of corresponding 5-ﬂuorouracil -untreated cells
(SW480, p<0.01; HT29, p<0.001) which, in turn, had a death
rate signiﬁcantly higher than that of cells exposed to 5-ﬂuoro-
uracil in the absence of macrophages or after co-culturing with
un-polarized macrophages (p<0.05 for both SW480 and
HT29).
Macrophages preliminarily cultured with the supernatant of
5-ﬂuorouracil-treated SW480 colorectal cancer cells and then
co-cultured with tumor cells displayed a cytotoxicity signiﬁ-
cantly greater (p<0.01) than that of control macrophages or of
macrophages pre-cultured with conditioned medium from 5-
ﬂuorouracil-untreated colorectal cancer cells (Fig. 3C and 3D).
The exposure of un-polarized (M0) macrophages to 5-ﬂuo-
rouracil increased the expression of the M1-marker HLA-DR
but not that of the M2-marker CD163 (Panel E), while drug-
exposure of M1-macrophages was accompanied by a signiﬁcant
release of TRAIL (p<0.01) and TNFa (p<0.05) pro-apoptotic
cytokines (Panel F).
Discussion
We ﬁrst report that densities of TAMs in the primary tumor
and in metastatic lymph nodes act as an independent predictive
factor in patients resected for stage III colorectal cancer and
treated with 5-ﬂuorouracil adjuvant therapy. Together with the
in-vitro evidence that macrophage greatly enhance colorectal
cancer cell killing by exposure to 5-ﬂuorouracil, clinical data
strongly support a synergism of TAMs with ﬂuoro-
pyrimidines.
In contrast to their association with poor prognosis in sev-
eral tumors, high densities of TAMs favorably inﬂuence the
postsurgical clinical outcome of colorectal cancer.19-24 The
present study clariﬁes that the association between high TAMs
densities and better survival in patients with stage III colorectal
cancer results from their interaction with 5-ﬂuorouracil, the
drug at the basis of adjuvant therapy for decades. Given that
such an association has been shown to be stage-dependent and
virtually limited to stage III disease,22-24 the synergism with 5-
ﬂuorouracil likely accounts for the entire prognostic value of
TAMs in colorectal cancer. Consistently, we found no correla-
tion between TAMs and outcome in our institutional cohort of
more than 2 hundred stage II patients (HR 0.98; 95% CI 0.88–
1.08; p D 0.66; data not shown).
Our results draw considerable strength from the fact that
TAMs exhibited their predictive role when measured at distinct
anatomic sites. Actually, high densities of macrophages in met-
astatic lymph nodes (LN-TAMs) were associated with disease-
free survival of 5-ﬂuorouracil-treated patients more closely
than high loads of TAMs measured in primary tumors (PT-
TAMs), which might reﬂect a more accurate identiﬁcation of
high-TAM inﬁltrates at the nodal invasive front. As to the den-
sity of LN-TAMs, Onishi and coll., reported that a high density
of CD169C, but not of CD68C, macrophages was associated
with better survival of patients with stage I-IV colorectal
Figure 1. Disease-free survival (DFS) in stage III colorectal cancer, by TAM-density quartiles. Kaplan-Meier Curves. Patients were stratiﬁed by quartile distribution of TAMs
densities at the invasive front of their primary tumor (PT-TAMs, upper panels) or of metastatic lymph-nodes (LN-TAMs, lower panels). Higher densities of both PT-TAMs
and LN-TAMs were signiﬁcantly associated with better disease-free survival in patients treated with 5-ﬂuorouracil (left panels), but not in the subset of untreated patients
(right panels). Also higher densities of tumor-associated neutrophils (PT-TANs) were weakly associated with the survival of 5-ﬂuorouracil -treated patients (see Fig. S1).
P values are for Log-Rank test.
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cancer. The lack of association of CD68C LN-TAMs with prog-
nosis is likely due to small study population, and to the absence
of stage stratiﬁcation with respect to chemotherapy treatment.42
The prognostic interaction of LN-TAMs anyhow supports the
concept that macrophages can synergize with 5-ﬂuorouracil in
metastatic microenvironment, where cytotoxic drugs are
expected to act. Supporting this interpretation, Cavnar et al.
recently reported the association between high-TAM inﬁltra-
tion of colorectal cancer liver metastases and better survival, in
a cohort of patients treated with peri-surgical chemotherapy.43
Noticeably, the overall predictive value of TAMs essentially
resulted from the excellent outcome of cancers with very high
densities of CD68C cells. Such cancers represented approxi-
mately 30% of the entire series (28.8 % by high PT-TAMs,
36.4% by high LN-TAMS), a fraction roughly equaling the
reduction in the relative risk of death that is expected from 5-
ﬂuorouracil adjuvant therapy in stage III colorectal cancer.
The densities of tumor-inﬁltrating CD3C lymphocytes
(TILs), although weakly correlated with PT-TAMs loads, had
no prognostic value in our series of stage III colorectal cancer.
This ﬁnding challenges the concept of a stage-independent cor-
relation between TILs and colorectal cancer prognosis,44 rather
indicating that the established protective role of TILs in stage II
disease13, 15, 44, 45 is lost once nodal metastases develop. In addi-
tion, the lack of prognostic impact for TILs densities in stage III
colorectal cancer implies that their correlation with PT-TAMs
is not extended to the very dense inﬁltrates of TAMs that
account for the prediction of 5-ﬂuorouracil responsiveness.
Taken together, results from combined analysis of CD3C and
CD68C cells support a disease model in which native immune
evasion accompanies the development of micro-metastases,
that can be best eradicated by adjuvant therapy in patients with
high TAM loads.
CD68 pan-macrophage marker does not allow the sub-clas-
siﬁcation of TAMs. However, in-vitro experiments indicate
that 5-ﬂuorouracil exposure favor macrophage polarization
toward a M1 anti-tumor role. These ﬁndings are in keeping
with in-vivo studies showing that the skewing of TAMs to
M1-like phenotype contributes to the anti-tumor and anti-
angiogenic effects of pharmacological agents in mice.35,36 Fur-
thermore, the unique exposure of colorectal cancer microenvi-
ronment to commensal enteric microbiota, which has been
recently shown to shape the immune cells response to cyto-
toxic agents,46,47 might contribute to TAMs polarization and
eventually account for the predictive value of macrophages in
colorectal cancer. On the other hand, TAMs subpopulations
are variably represented in distinct microenvironments of the
same tumor,46 and expression of polarization markers is con-
siderably heterogeneous in colorectal cancer.23 Accordingly,
the polarization of TAMs in the resected primary tumor might
even be irrelevant to their successive synergism with post-sur-
gical chemotherapy, so that TAMs densities might simply pre-
dict the likelihood of a robust response toward micro-
metastases. This situation somehow resembles the one occur-
ring in follicular lymphoma, in which administered therapeutic
regimes skew the predictive role of CD68C TAMs (refs 24-26). In
a wider perspective, our data add to those pointing to the involve-
ment of tumor targeting immune responses in determining the
clinical efﬁcacy of conventional chemotherapy regimens, besides
their cytostatic and cytotoxic effects.48,49 The pathways mediating
the interaction of macrophages with 5-ﬂuorouracil remain to be
identiﬁed, although the release of TNFa/TRAIL in vitro by M1
macrophages exposed to 5-ﬂuorouracil suggests the involvement
of these molecules in immunogenic cell death of colorectal cancer
cells.50
The study is limited by the size of the external validation set,
and by the fact that most patients were treated with 5-ﬂuoro-
uracil alone (93.2% in the institutional cohort, 63.1% in the val-
idation set). At any event, the prevailing impact of 5-
ﬂuorouracil in reducing the progression of stage III colorectal
cancer makes it likely TAMs would maintain a strong predic-
tive value also in cohorts of patients treated with oxaliplatin
combination. Due to the relevant clinical implication of the
lack of substantial survival beneﬁt of adjuvant therapy in
patients with low-TAM, our ﬁndings deserve validation in
pathological archives from randomized controlled trials.
This study conﬁrms that intra-tumoral densities of neutro-
phils (TANs), another native component of the immune inﬁl-
trate of colorectal cancer, are weakly associated with better
outcome in 5-ﬂuorouracil-treated patients. However, the loss of
TANs predictive value at multivariate analysis endorses TAMs
as the most promising marker of response to adjuvant therapy.
Figure 2. Disease-free survival (DFS) in 5-ﬂuorouracil-treated patients with stage III
colorectal cancer, by high/low TAMs. Kaplan-Meier Curves. Patients were classiﬁed
by high/low density of TAMs, measured at the invasive front of their primary colo-
rectal cancer (PT-TAMs) or of metastatic lymph-nodes (LN-TAMs), and deﬁned by
optimal cut-offs at receiver operator characteristic (ROC) curves (Fig. S2). P values
are for Log-Rank test. Also high densities of intra-tumoral neutrophils (PT-TANs)
were weakly (p D 0.04) associated with better disease-free survival (Fig. S3). The
association of high PT-TAMs with better disease-speciﬁc survival was conﬁrmed in
the external validation set (Fig. S4).
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Figure 3. Chemotherapy and macrophage synergism in cytotoxic function in vitro. A) Facs plots of SW480 colorectal cancer cells co-cultured with un-polarized (M0) or
macrophages polarized toward a cytotoxic phenotype by IFNg/LPS stimulation (M1). Tumor cell death was evaluated by Annexin V/7-AAD staining. 24-hour 5-ﬂuorouracil
treatment on colorectal cancer cells alone did not signiﬁcantly increase tumor cell death compared with untreated cells (top). Macrophages induced detectable tumor
cell death, which was further enhanced by treatment with 5-ﬂuorouracil (bottom). One representative of 5 experiments is shown. B) Histograms representative of 3 inde-
pendent experiments performed with 2 MSS cell lines (SW480 and HT29): cytotoxicity of M1 macrophages toward colorectal cancer cells (; P  0.05) was signiﬁcantly
increased by the addition of 5-ﬂuorouracil in the 2 microsatellite stable cell lines, SW480 (; P  0.005) and HT29 (P  0.001). Histograms show means § standard
error. C) Culture of macrophages with supernatant of 5-ﬂuorouracil-treated colorectal cancer cells (MfCM) signiﬁcantly increased macrophage cytotoxicity (right) compared
with control macrophages (left) or macrophages cultured with supernatant of control colorectal cancer cells (MfCT) (middle). One representative of 2 experiments is
shown. D) Histograms representative of 2 independent experiments (; P  0.001; ; p  0.01). E) Effect of chemotherapy on macrophage polarization markers. 5-Fluo-
rouracil treatment of M0 macrophages increased the expression of the M1-marker HLA-DR, while the M2-marker CD163 did not shown any change. F) Effect of chemo-
therapy on macrophages-M1 cytotoxicity. TRAIL and TNFa expression was measured by ELISA in cellular extracts from macrophages stimulated with LPS/IFNg and
subsequently exposed to 5-ﬂuorouracil for 24 hours. One representative of 2 experiments is shown. Bars represent means§ standard error. (: p <0.05; : p  0.01).
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By revealing that high densities of TAMs strongly predict
the efﬁcacy of 5-ﬂuorouracil in stage III colorectal cancer, we
provide an explanation for the unique prognostic association of
TAMs with colorectal cancer outcome, contributing a step
toward the personalized management of the disease. In particu-
lar, the measurement of TAMs in metastatic lymph nodes is
proposed as an independent and powerful tool to forecast che-
motherapy efﬁcacy. Our results also encourage evaluating
immune-therapeutic interventions aimed at TAMs recruitment
and polarization as a way to improve the response rate of node-
positive colorectal cancer to 5-ﬂuorouracil-based adjuvant
therapy.
Materials and Methods
Tissue samples and patients
The study was conducted on specimens of primary tumor and
of metastatic lymph nodes obtained from a consecutive series
of 208 patients resected for stage III colorectal cancer at the
Humanitas Research Hospital between 1997 and 2006. Tissues
from patients having undergone neo-adjuvant chemo-radio-
therapy for rectal cancer were excluded from the series to avoid
possible interferences with TAMs. After study approval by the
Hospital Ethics Committee, the informed consent to tissue
analysis and data treatment was obtained from each patient by
the referring physician or by a clinician involved in the study.
Patient demographics and tumor pathological features were
available at the hospital intranet system. The same source pro-
vided most of clinical data relative to post-surgical treatment
and follow-up.
The administration of 5-ﬂuorouracil-based adjuvant therapy
was always prescribed on clinical grounds and not in the con-
text of prospective trials. Adjuvant therapy was less frequently
(p<0.001) administered to 70-year old patients (39/90, 43%)
than to younger patients (107/118, 90.7%). Only in 10 of 146
(6.8%) treated patients oxaliplatin was part of the therapeutic
regimen. The 5-year follow-up schedule, as ordered at dis-
charge, included yearly abdominal CT scan (with abdominal
US at 6 months), yearly thorax imaging (X-rays or CT scan),
quarterly measurement of CEA levels, and biannual clinical
evaluation. The mean ( § SD) follow-up of patient included in
the study was 4.82 § 2.56 y. External institutions, referring
physicians or patient families were contacted to obtain clinical
data not available in hospital records. The database was ﬁnally
completed with data on tumor microsatellite status, K-RAS
(codon12 and 13), and BRAF mutation status (codon 1799 hot
spot) determined by the Laboratory of Molecular Gastroenter-
ology, as described previously.51
Primary-tumor tissues were also obtained from 2 external
cohorts of stage III colorectal cancer. Eighty-two tissue sections
were collected from the Department of Medical Biosciences of
the University of Umea

(Sweden), while 29 colorectal cancer
tissue micro-arrays came from the Institute of Pathology of the
University of Bern (Switzerland). Tissues from these subsets
were merged to create a validation set external to the original
cohort. Demographics, pathological data and disease-speciﬁc
survival were made available for corresponding patients. Also
among these patients, 5-ﬂuorouracil-based adjuvant therapy
was prescribed according to recommendations in force at the
time of surgery, and oxaliplatin was part of the adjuvant ther-
apy in 22 of 60 (36.7%) patients. The mean ( § SD) follow-up
in the overall external set was 4.82 § 2.56 y.
Immunohistochemical staining
Serial sections of formalin-ﬁxed and parafﬁn-embedded tissues
were preliminary stained with hematoxylin-eosin to select areas
adequately representing the tumor invasive front. Adequate
sections were obtained from all the 208 primary tumors and
from 149 matched metastatic lymph nodes, nodal micrometa-
stasis being insufﬁciently represented in the archive material of
59 patients.
Immediately adjacent tissue sections were used for immuno-
histochemical analysis. For each specimen, 2-mm thick forma-
lin-ﬁxed sections were de-parafﬁned, rehydrated and exposed
to an antigen-retrieval system (Diva Decloaker solution, Bio-
care Medical). After blocking endogenous peroxidase (Peroxi-
dazed-1 and Background Sniper, Biocare Medical), slides were
incubated at room temperature with 3% hydrogen peroxide for
10 minutes and then with 1:50 PBS-diluted primary monoclo-
nal antibody (anti-CD68, KP-1 clone, Dako) for 60 minutes.
Figure 4. Immunostaining of CD68C TAMs at the invasive margin of primary colo-
rectal cancer (A) and of metastatic lymph-nodes (B). Examples of tissue areas with
variable extent of CD68-immunoreative area (% IRA in white boxes).
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After exposure to MACH 4 Universal HRP Polymer (Biocare
Medical) for 30 minutes at room temperature Space Import-
Export, Italy) to reveal bound antibodies, 30-diaminobenzidine
tetrahydrochloride was used as a chromogen (DABchromogen
X50, ChemMate, Dako) and nuclei were lightly counterstained
with a freshly made hematoxylin solution (Harris Hematoxylin,
DiaPath).
Staining for TANs and CD3C TILs was respectively per-
formed with an anti-CD66b monoclonal antibody (clone
G10F5; BD Pharmingen, CA) in 200 specimens of primary
Table 2. Outcome predictors in 5-ﬂuorouracil-treated patients with stage III colorectal cancer (Cox univariate analysis).
Disease-Free Survival Institutional Cohort (n D 146) Disease-Speciﬁc Survival External Validation Set (n D 60)
No. of Recurrences (%) HR (95% CI) p No. of Deaths (%) HR (95% CI) p
Densities of Tumor-Associated Macrophages (TAMs) and Neutrophils (TANs)
PT-TAMsa low 40/104 (38.5) 1 (reference) 0.002 22/49 (44.9) 1 (reference) 0.05
high 4/42 (9.5) 0.20 (0.07–0.57) 1/11 (9.1) 0.14 (0.02–1.00)
LN-TAMsa low 32/68 (47.1) 1 (reference) 0.001 NA
high 3/39 (7.7) 0.12 (0.04–0.41)
PT-TANsb low 34/101 (33.7) 1 (reference) 0.04 NA
high 6/40 (15.0) 0.41 (0.17–0.97)
Patient Demographics
Age 70 yrs. 14 /35 (40.0) 1 (reference) 0.15 5/14 (35.7) 1 (reference) 0.47
<70 yrs. 30/111 (27.0) 0.63 (0.33–1.18) 18/46 (39.1) 0.69 (0.25–1.88)
Gender male 27/91 (29.7) 1 (reference) 0.84 9/27 (33.3) 1 (reference) 0.38
female 17/55 (30.9) 1.06 (0.58–1.95) 14/33 (42.4) 1.45 (0.63–3.36)
Tumor Pathology
Site distal 28/96 (29.2) 1 (reference) 0.59 17/41 (41.5) 1 (reference) 0.71
proximal 16/50 (32.0) 1.18 (0.64–2.19) 6/19 (31.6) 0.83 (0.33–2.13)
Local Invasion pT3 34/122 (27.9) 1 (reference) 0.13 17/47 (36.2) 1 (reference) 0.14
pT4 10/24 (41.7) 1.72 (0.85–3.49) 6/13 (46.1) 2.05 (0.80–5.31)
Nodal Invasion N1 21/99 (15.1) 1 (reference) < 0.001 9/32 (28.1) 1 (reference) 0.03
N2 23/47 (48.9) 2.74 (1.52–4.96) 14/28 (50.0) 2.50 (1.08–5.80)
Grade G1/G2 30/111 (27.0) 1 (reference) 0.13 13/38 (34.2) 1 (reference) 0.35
G3 14/35 (40.0) 1.62 (0.86–3.07) 10/22 (45.4) 1.48 (0.65–3.38)
Cell-Type ADC 38/127 (29.9) 1 (reference) 0.83 11/34 (32.3) 1 (reference) 0.77
variants 6/19 (31.6) 1.10 (0.46–2.60) 12/26 (46.1) 0.88 (0.38–2.04)
Density of TILsc(quartiles) 1st-to-3rd 31/107 (26.4) 1 (reference) 0.51 NA
4th 13/39 (27.8) 1.24 (0.65–2.37)
Vascular Invasion no 25/104 (24.0) 1 (reference) 0.008 16/50 (32.0) 1 (reference) 0.05
yes 19/42 (45.2) 2.24 (1.23–4.08) 7/10 (70.0) 2.47 (1.01–6.01)
Tumor Molecular Features
MS Status MSS 41/129 (31.8) 1 (reference) 0.34 22/54 (40.7) 1 (reference) 0.19
MSI 41/129 (31.8) 0.57 (0.18–1.84) 1/6 (16.7) 0.26 (0.04–1.97)
BRAF wild-type 41/139 (29.5) 1 (reference) 0.27 9/24 (37.5) 1 (reference) 0.77
mutated 3/7 (42.9) 1.93 (0.60–6.24) 2/3 (66.6) 1.26 (0.27–5.96)
K-RAS wild-type 27/94 (28.7) 1 (reference) 0.89 NA
mutated 14/47 (29.8) 1.05 (0.55–2.00)
NA, not available
apercent CD68-immunoreactive area at the invasive front of primary tumors (PT-TAMs) or of metastatic lymph nodes (LN-TAMs, n D 107); low and high deﬁned by an
optimal cut-off of 8.0% for PT-TAMs and of 3.7% for LN-TAMs (see Receiver Operator Characteristic curve, Fig. 4)
bpercent CD66b-immune-reactive area in the intratumoral compartment (PT-TANs, nD 141); low and high deﬁned by an optimal cut-off of 1.16 % (see Receiver Operator
Characteristic curve, Fig. 4)
c1st and 2nd quartiles not deﬁnable due to the absence of detectable immunoreactivity in 80 of 200 tested tissues
Table 3. Cox multivariate analysis of TAM and TAN densities, and other pathological features predicting the outcome of stage III colorectal cancer treated with 5-ﬂuoro-
uracil adjuvant therapya
Biomarker (High vs. Low) Nodal Status (N2 vs. N1) Vascular Invasion (Y vs. N)
HR (95% CI) p HR (95%CI) p HR (95%CI) p
A. Disease-Free Survival in the Institutional Cohort
by PT-TAMsb 0.23 (0.08–0.65) 0.005 2.43 (1.34–4.42) 0.001 2.02 (1.11–3.68) 0.02
by LN-TAMsb 0.13 (0.04–0.43) 0.001 2.35 (1.19–4.63) 0.01 2.36 (1.21–4.62) 0.01
by TANsc 0.53 (0.22–1.30) 0.17 2.47 (1.31–4.67) 0.005 2.29 (1.22–4.30) 0.01
B. Disease-Speciﬁc Survival in the External Validation Set
by PT-TAMsb 0.14 (0.02–1.00) 0.05 2.54 (1.09–5.90) 0.03 1.57 (0.58–4.21) 0.37
aDistinct models were constructed to weight the predictive value of each candidate biomarker. Only variables with a p value less than 0.10 at univariate analysis (see
Table 3) were entered.
bpercent CD68-immunoreactive area (IRA) at the invasive front of the primary tumor (PT-TAMs) or of metastatic lymph nodes (LN-TAMs). Low vs. high densities are deﬁned
by optimal cut-offs from Receiver Operator Characteristic curves (8.0% IRA for PT-TAMS and 3.7% IRA for LN-TAMs)
cpercent CD66b-immunoreactive (IRA) within the primary tumor (TANs). Low vs. high densities are deﬁned by optimal cut-offs from Receiver Operator Characteristic
curves (1.16% IRA )
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tumors and with a monoclonal antibody (clone F7.2.38, M7254;
Dako) in 208 tissue sample of primary tumors, as described
previously13,39 (Fig. S5).
Computer-aided image analysis
An expert pathologist (M. R.) who was completely blind to clin-
ical data selected 3 non-contiguous microscopic areas of CD68-
stained slides. At 10x magniﬁcation, cancer tissue was to repre-
sent approximately 50% of each microscopic ﬁeld both for the
invasive front of primary tumors and for metastatic nodal nests
(Fig. 4). A digital image (1280 £ 960 pixels, 2.21 pixel/micron
resolution) covering 0.25 mm2 of each selected area, was
obtained by a 5-megapixel color camera (Olympus XC50). An
ad hoc software developed at the Humanitas Research Hospital
(patent WO 2005 006255), using a segmentation algorithm
based on RGB (red, green and blue) scale, was used to automat-
ically measure the immune-reactive area in digitized images.13
In calculating the percent immune-reactive area (% IRA), the
system corrected microscopic images for unﬁlled natural holes,
vascular spaces, or histological artifacts (Fig. 5). The value of %
CD68-IRA attributed to each tumor or nodal specimen was the
mean of values found at analysis of 3 distinct microscopic
ﬁelds. The value of % CD66b-IRA for TANs was similarly cal-
culated as the mean of 3 distinct intra-tumoral regions.39
In-vitro experiments
Human mononuclear cells were obtained from the peripheral
blood of healthy volunteers by gradient centrifugation with
Histopaque-1077 (Sigma-Aldrich, Milan, Italy). Monocytes
were isolated using the Monocyte Isolation Kit II (MACS Milte-
nyi Biotec, Italy), and residual T and B cells were removed by
plastic adherence. Monocytes were differentiated into macro-
phages by 6-day incubation with macrophage colony-stimulat-
ing factor (M-CSF, Tebu-Bio, Italy) at the concentration of
100 ng/ml. Polarization of macrophages toward the M1-like
phenotype was obtained on day 6 by stimulating macrophages
with interferon-gamma (IFNg, 25 ng/ml, Tebu-Bio, Italy) for
20-hour and with lipopolysaccharides (LPS, 50 ng/ml) for
4 hours.
HT29 and SW480 colorectal cancer cells, obtained by
ATCC, were cultured in RPMI-1640 medium (Euroclone,
Italy) supplemented with 10% fetal bovine serum (FBS). After
labeling with the ﬂuorescent cell tracer carboxyﬂuorescein
diacetate succinimidyl ester (CFSE, Becton Dickinson, Italy),
cells were co-cultured with M1 macrophages, at a 1:1 ratio, in
10% FBS medium for 24 hours. To test the early effect of 5-
ﬂuorouracil on cell viability, 2,4-dihydroxy-5-ﬂuoropyrimidine
(5-ﬂuorouracil, Sigma-Aldrich, Italy) at a 10 mM concentration
was added to tumor cells alone or in co-culture with M1 macro-
phages. To see whether the cytotoxic effect of macrophages was
enhanced by cell treatment with 5-ﬂuorouracil, the superna-
tants of SW480 cells treated with 20 mM 5-ﬂuorouracil for
72 hours, or of untreated cells as a control, were added in a 1:3
ratio to the medium of differentiated macrophages, before 24-
hour co-culturing on day 6. The rate of tumor cell death was
assessed by ﬂow cytometry. To restrict the analysis of dead cells
to CFSE-labeled tumor cells, co-cultured macrophages were
labeled with an anti-HLA-DR-PE human antibody (clone
AC122, Miltenyi Biotec, Italy). After cell staining for annexin-
V and 7-aminoactinomycin, dead tumor cells were quantiﬁed
by a FACS Canto System (Becton Dickinson, Italy).
To assess the effect of 5-ﬂuorouracil on macrophage polari-
zation and on the expression of apoptosis-related cytokines,
macrophages were exposed to 20 mM 5-ﬂuorouracil for
24 hours. For subsequent analysis of HLA-DR and CD163
polarization markers, M0 macrophages were preliminary incu-
bated with 1% human serum on ice for 20 minutes to block Fc-
receptor sites. Cells were then washed with FACS buffer
(PBS-/- C 0,5% BSA C 0,05% Sodium Azide), centrifuged at
1300rpm for 5 minutes, incubated with staining antibodies
(mouse anti-human CD16-PercPcy5, 3G8 clone, as isotype
control; HLA-DR-PE, G46–6 clone; CD163-BV421, GHI/61
clone - Becton Dickinson, Italy) on ice for 20 minutes, and
washed with FACS buffer. Stained cells were ﬁnally measured
using FACS Canto System and FlowJo single-cell analysis soft-
ware. For analysis of 5-ﬂuorouracil-induced changes in cyto-
kines, M1-polarized macrophages were washed from LPS- and
IFNg and then cellular extracts were tested for protein-normal-
ized levels of TRAIL and TNFa by speciﬁc ELISA assays (Pro-
dotti Gianni, Italy).
Statistical analysis
The Mann-Witney test was used to analyze the associations of
CD68C TAMs densities with patient demographics and with
pathological or molecular features of colorectal cancer. A
receiver operating characteristic (ROC) curve was constructed
to check the predictive performance of CD68-immunoreactive
area in patients with stage III cancer. Cox proportional hazard
models were used to evaluate TAMs densities, other molecular,
clinical-pathological variables and their interactions, as out-
come predictors. Cox multivariate analysis was done by enter-
ing only variables with a p value less than 0.10 at univariate
analysis. By a backward step-wise elimination approach, non-
signiﬁcant variables were removed from the model. Disease-
free-survival and disease-speciﬁc survival were calculated from
diagnosis until March 1, 2014, which was the date of data cen-
soring. Kaplan-Meier curves were plotted and log-rank test
were used to analyze the survival of colorectal cancer patients
grouped according to TAM densities. The Students’ t test was
used to compare rates of in vitro cell death in different experi-
mental settings. All the statistical analyses were performed
Figure 5. Capture of immune reactive areas at image analysis. Example of com-
puter assisted selection of immune reactive areas spots by red green and blue
(RGB) color segmentation of the original digital microphotograph. Immune-reac-
tive area, brown. Not stained tissue, yellow. The percent ratio between immune
reactive areas and total area was automatically calculated.
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using STATA (version 13.1). For each statistical test, 2-sided P
values < 0.05 were considered statistically signiﬁcant.
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